High-throughput screening (HTS) is an automated drug discovery technique for identification of active compounds against a compound library. Use HTS readers and integrated assay preparation / analysis workstations to screen your compounds. Identify active compounds against various HTS libraries, including membranes, proteins and peptides and HTS cell lines. Find the best high-throughput screening products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.
Cell Membranes - Custom Preparation of Cell Membranes from CCS Cell Culture Service Preparations membranes from cell which are expressing a target receptor, transporter or ion channel at a high density are a useful tool in drug research. Embedded in a membrane fragment or vesicle the proteins remain in a functional native confirmation. Ligand binding assay and functional GTP-gammaS assays can be performed with these preparati…
SCOPE, Structure-based compound optimization prioritization and evolution is an innovation from VLife to overcome challenges in lead optimization. SCOPE provides the user a way to address known problems like poor correlation between energy and activity, insensitive docking scoring functions for molecule prioritization and insufficient clues in ligand design for improvement in activity. SCOPE smartly understands the information…
Human Cav2.2/β3/α2δ calcium ion channel-expressing, stable replicating cell line (CHO-K1). Cat#: CT6159. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: PatchXpress® , QPatch HT™ , FLIPR®
Human Nav1.8/b3 sodium ion channel-expressing, stable replicating cell line (CHO-K1). Cat#: CT6011. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: PatchXpress® , QPatch HT™ , IonWorks Quattro®
Human a3/β4 Nicotinic Acetylcholine Receptor-expressing, stable replicating cell line (CHO-K1). Cat#: CT6021. Cryopreserved cells, 6x10E6 cells/vial. Platform validation: QPatch HT™
Human GABAA (α5β2γ2) Receptor-expressing, stable replicating cell line (CHO-K1). Cat#: CT6119. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: FLIPR®
Human GABAA (a5β2γ2) Receptor-expressing, stable replicating cell line (CHO-K1). Cat#: CT6119. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: FLIPR®
Human Cav2.2/b3/a2d calcium ion channel-expressing, stable replicating cell line (CHO-K1). Cat#: CT6159. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: PatchXpress® , QPatch HT™ , FLIPR®
Human Cav2.1/b4/a2d calcium ion channel-expressing, stable replicating cell line (CHO-K1). Cat#: CT6196. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: PatchXpress® , QPatch HT™
Human GABAA (α3/β2/γ2) Receptor-expressing, transiently transfected cells (HEK293). Cat#: CT7022. Cryopreserved cells, 6x10E6 cells/vial. Platform validation: PatchXpress®, FLIPR®
Human a7 Nicotinic Acetylcholine Receptor-expressing, stable replicating cell line (CHO-K1). Cat#: CT6201. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: QPatch HT™ , FLIPR®
Human Cav2.1/β4/α2δ calcium ion channel-expressing, stable replicating cell line (CHO-K1). Cat#: CT6196. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: PatchXpress® , QPatch HT™
Human Nav1.8/β3 ion channel-expressing, division-arrested cells (CHO-K1). Cat#: CT4011. Three vials of Cyropreserved irradiated cells, 2x10E6 cells/vial (6x10E6 cells total). Platform validation: PatchXpress®
Human α3/β4 Nicotinic Receptor-expressing, division-arrested cells (CHO-K1). Cat#: CT4021. Cryopreserved irradiated cells, 6 million cells per vial.. Platform validation: FlexStation III
Human GABAA (α5/β2/γ2) ion channel-expressing, division-arrested cells (CHO-K1). Cat#: CT4119. Cryopreserved irradiated cells, 6 million cells per vial.. Platform validation: FlexStation III
Human GABAA (a5/b2/g2) ion channel-expressing, division-arrested cells (CHO-K1). Cat#: CT4119. Cryopreserved irradiated cells, 6 million cells per vial.. Platform validation: FlexStation III
Human Cav2.2/b3/a2d1 ion channel-expressing, division-arrested cells (CHO-K1). Cat#: CT4159. Three vials of Cyropreserved irradiated cells, 2x10E6 cells/vial (6x10E6 cells total). Platform validation: PatchXpress®
Human GABAA (α2β2γ2) Receptor-expressing, stable replicating cell line (CHO-K1). Cat#: CT6118. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: FLIPR®
Human α7+RIC-3 Nicotinic Receptor-expressing, division-arrested cells (CHO-K1). Cat#: CT4201. Cryopreserved irradiated cells, 6 million cells per vial.. Platform validation: FlexStation III
Human GABAA (a3/b2/g2) Receptor-expressing, transiently transfected cells (HEK293). Cat#: CT7022. Cryopreserved cells, 6x10E6 cells/vial. Platform validation: PatchXpress®, FLIPR®
Human b2 Adrenergic Receptor-expressing GPCR (G protein-coupled receptor) stable, replicating cell line (CHO-K1). Cat#: A600. Cryopreserved cells, 6 million cells per vial
Human b2 Adrenergic Receptor-expressing GPCR (G protein-coupled receptor) division-arrested cells (CHO-K1). Cat#: A400. Cryopreserved irradiated cells, 6 million cells per vial
Human a3/β4 Nicotinic Receptor membrane preparation derived from stable, replicating cell line. (Cat#: CT3021)
Human NCX1 Na+/Ca2+ Exhanger-expressing, stable replicating cell line (HEK293). Cat#: CT6206. Cryopreserved cells, 3 vials: 2x10E6 cells/vial. Platform validation: FLIPR®
Human NCX1 Na+/Ca2+ Exhanger-expressing, transiently transfected cells (HEK293). Cat#: CT7206. Cryopreserved cells, 6x10E6 cells/vial. Platform validation: Manual Patch Clamp, FLIPR®
